Analytical Data
-
基因名
CD133/PROM1
- Application
-
别名
CD133; PROML1; Macular Dystrophy,Retinal 2; Stargardt Disease 4(Autosomal Dominant); Prominin-like protein 1; Antigen AC133
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O43490
-
表达区间
Ile171~Asp431
-
分子量
28kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD133, also known as PROM1, is a transmembrane glycoprotein prominently expressed in stem cells and certain types of cancer cells, making it a critical marker in cancer research and regenerative medicine. Its role in maintaining stem cell properties and regulating cell differentiation has piqued the interest of scientists aiming to understand its involvement in tumorigenesis and tissue regeneration. The presence of CD133+ cells in various tumors, such as glioblastoma and colorectal cancer, indicates its potential as a target for cancer therapies, particularly in the context of cancer stem cells that contribute to tumor recurrence and metastasis. Recombinant CD133/PROM1 proteins have been developed to facilitate the study of its biological functions and interactions at the molecular level, allowing researchers to elucidate signaling pathways and mechanisms of action. Additionally, these proteins can serve as valuable tools for developing diagnostic and therapeutic strategies, including the creation of targeted drugs and vaccines. Overall, the ongoing research on CD133/PROM1 recombinant proteins holds promise for advancing our understanding of stem cell biology and improving clinical outcomes in cancer treatment.
